Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Non-Current Assets (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Non-Current Assets readings, the most recent being $1.9 million for Q4 2017.

  • On a quarterly basis, Non-Current Assets rose 4013.04% to $1.9 million in Q4 2017 year-over-year; TTM through Dec 2017 was $6.1 million, a 232.62% increase, with the full-year FY2017 number at $1.9 million, up 4013.04% from a year prior.
  • Non-Current Assets hit $1.9 million in Q4 2017 for Eledon Pharmaceuticals, down from $2.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $2.0 million in Q2 2017 to a low of $46000.0 in Q4 2016.
  • Median Non-Current Assets over the past 5 years was $654000.0 (2015), compared with a mean of $734866.7.
  • Biggest five-year swings in Non-Current Assets: plummeted 94.28% in 2016 and later surged 4013.04% in 2017.
  • Eledon Pharmaceuticals' Non-Current Assets stood at $109000.0 in 2013, then soared by 113.76% to $233000.0 in 2014, then surged by 245.06% to $804000.0 in 2015, then plummeted by 94.28% to $46000.0 in 2016, then surged by 4013.04% to $1.9 million in 2017.
  • The last three reported values for Non-Current Assets were $1.9 million (Q4 2017), $2.0 million (Q3 2017), and $2.0 million (Q2 2017) per Business Quant data.